Fig. 3: The pooled seroconversion rate following SARS-CoV-2 booster vaccination in patients with hematologic malignancies. | Blood Cancer Journal

Fig. 3: The pooled seroconversion rate following SARS-CoV-2 booster vaccination in patients with hematologic malignancies.

From: Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Fig. 3

The pooled analysis of 21 studies containing 1518 patients with hematologic malignancies showed that the pooled seroconversion rate after booster vaccination was 40.5% (95% confidence interval [CI], 33.0–48.4%).

Back to article page